Nymox Pharmaceutical Corp. (NYMX) Sees Large Increase in Short Interest

Nymox Pharmaceutical Corp. (NASDAQ:NYMX) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 2,687,901 shares, an increase of 30.4% from the August 15th total of 2,061,639 shares. Based on an average daily volume of 3,887,445 shares, the short-interest ratio is presently 0.7 days. Approximately 6.2% of the company’s shares are sold short.

Shares of Nymox Pharmaceutical Corp. (NASDAQ:NYMX) opened at 3.43 on Friday. The stock’s market capitalization is $158.28 million. The stock has a 50 day moving average of $3.13 and a 200 day moving average of $2.78. Nymox Pharmaceutical Corp. has a 52-week low of $1.62 and a 52-week high of $5.79.

In related news, Director James George Robinson bought 22,500 shares of the company’s stock in a transaction dated Friday, July 29th. The stock was purchased at an average cost of $3.86 per share, with a total value of $86,850.00. Following the transaction, the director now owns 2,880,050 shares in the company, valued at approximately $11,116,993. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 54.00% of the stock is currently owned by insiders.

Nymox Pharmaceutical Corp. Company Profile

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

5 Day Chart for NASDAQ:NYMX

Receive News & Ratings for Nymox Pharmaceutical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.